

# in urinary infections 'clearly superior' to ampicillin or sulphadimidine



#### Higher cure rates

These comparative results were obtained in treating hospital in-patients with UTI<sup>1</sup>, most of whom were infected with entrenched hospital pathogens.

85% cure rate	SEPTRIN*
70% cure rate	ampicillin
40% cure rate	sulphadimidine

(Cure criterion = eradication of original organism 1 week after treatment ended.)

SEPTRIN was "clearly superior to either of the other treatments" and this superior effect was "even more appreciable in the re-treatment of patients who had failed on another drug."<sup>2</sup>

SEPTRIN Tablets, SEPTRIN Paediatric Suspension and SEPTRIN Paediatric Tablets contain trimethoprim and sulphamethoxazole. Full information is available on request.

References: 1. *Brit med J*, (1969) 1, 541.

2. *Leading Article, Brit med J*, (1969) 1, 525.

\*Trade Mark

#### Clear reasons for using Septrin

Abstracted from a Leading Article in the *British Medical Journal*<sup>2</sup>.

- Trimethoprim not only attains therapeutic tissue levels, but is excreted unchanged in high concentration in the urine.
- All Gram-negative bacilli occurring in the urine, except *Pseudomonas aeruginosa*, are usually highly sensitive to it.
- Its minimum inhibitory concentration is extremely low.
- Trimethoprim and a sulphonamide, by blocking successive stages in the same bacterial metabolic process, exert a strong synergic effect, and this action is bactericidal.



Burroughs Wellcome & Co.  
(The Wellcome Foundation Ltd.) Dartford, Kent

for bacterial infections  
**Septtrin**  
an advance on the antibiotics

# Salazopyrin<sup>®</sup>

in the whole spectrum  
of ulcerative colitis ...



*mild... moderate...  
severe (fulminating)...  
relapse.*

"Among measures designed to prevent relapse small doses of corticosteroids are useless, and larger doses carry the risks of the therapy. (Salazopyrin) has been shown to reduce the relapse rate greatly when used in a maintenance dose . . . over a period of one year".  
Brit. med. J. (1968) 2, 539-542, 605-607.

Salazopyrin (sulphasalazine) is available as the plain 0.5 g. tablet, as the 0.5 g. EN-tab and as an 0.5 g. suppository.

Literature and detailed information on Salazopyrin are available on request.

Pharmacia (Great Britain) Ltd,  
Paramount House, 75 Uxbridge Road,  
London W.5.  
Telephone: 01-579 0102/7.



Pharmacia

## A CONFERENCE ON THE ADVANCE IN ORTHOTICS

will be held at the University of Dundee from 21st to 25th June, 1971

Sponsored by the Eastern Regional Hospital Board and in association with the Scottish Home and Health Department and the University of Dundee.

The Conference will outline and review the various locomotor and functional disabilities which may require prescription of orthotic devices.

Emphasis will be placed on the assessment and description of functional incapacity, prescription techniques, a realistic appreciation of the functional advantages and disadvantages of the presently accepted apparatus, description and demonstration of new and advanced designs and the formulation of guidelines for research, development and design for the future. At the same time the place of orthotic management *vis-a-vis* surgical treatment, in certain specified conditions and in relation to the growth period will be explored. An international team of experts representing all relevant disciplines has been assembled to ensure comprehensive discussion.

The Conference proceedings will be dealt with under the following headings:

Biomechanical Matching	Cerebral Palsy
Rationale of Prescription	Spina Bifida
Upper Extremity Orthotics	First Aid
Lower Extremity Orthotics	Rheumatoid Arthritis
Spinal Bracing	Orthotics and the Elderly
Wheelchairs	Paraplegia
Fracture Bracing	Club Foot

Administration, Supply and the Clinic Team

The Conference is properly multidisciplinary and is intended for general and orthopaedic surgeons, physical medicine specialists, prosthetists, orthotists or orthopaedic technicians, therapists and remedial gymnasts, biomedical engineers and others with a stated interest in the field.

It is anticipated that the consolidated registration fee inclusive of board and accommodation will be of the order of £35.

Excellent hostel accommodation is available. Details may be obtained from the Dundee Limb Fitting Centre, 133 Queen Street, Broughty Ferry, Dundee, Scotland.

## THE QUARTERLY JOURNAL OF MEDICINE

D. A. K. BLACK  
W. B. MATTHEWS

EDITED BY  
P. HUGH-JONES  
J. D. N. NABARRO

E. M. MCGIRR  
A. G. W. WHITFIELD

### CONTENTS

NEW SERIES. VOL. XXXIX. No. 156. OCTOBER, 1970  
(Vol LXIII of the continuous series)

Schönlein-Henoch Purpura in the Adult. By J. J. Cream, J. M. Gumpel, and R. D. G. Peachey. With Plates 36 to 38

The Effect of Posture on Subjects with Cerebrovascular Disease. By Maurice Gross. With Plates 39 to 41

Ruptured Aneurysm of the Sinus of Valsalva. By J. S. Wright. With Plates 42 to 45

Neuropsychiatric and Electroencephalographic Changes after Transplantation of the Liver. By J. D. Parkes, I. M. Murray-Lyon, and Roger Williams

Vitamin-D-resistant Osteomalacia as a Cause of Cord Compression. By J. H. Highman, P. H. Sander-son, and M. M. L. Sutcliffe. With Plates 46 to 51

The Late Results of Medical and Surgical Treatment for Bleeding Duodenal Ulcer. By R. F. Harvey, and M. J. S. Langman

Dubin-Johnson Syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. By Mordechai Shani, Uri Seligsohn, Eliahu Gilon, Chaim Sheba, and Avinoam Adam

Dubin-Johnson Syndrome in Israel. II. Association with Factor-VII Deficiency. By Uri Seligsohn, Mordechai Shani, Bracha Ramot, Avinoam Adam, and Chaim Sheba

Glomerular Coagulation in Acute Ischaemic Renal Failure. By A. R. Clarkson, Mary K. MacDonald, V. Fuster, J. D. Cash, and J. S. Robson. With Plates 52 to 63

Osteoporosis and the Effects of Ageing on Bone Mass in Elderly Men and Women. By Peter Adams, G. T. Davies, and P. Sweetnam

The Association of Physicians of Great Britain and Ireland 1970 Sixty-Fourth Annual General Meeting

Price £1 10s. net. Subscription price £4 5s. per annum.

OXFORD UNIVERSITY PRESS

ELY HOUSE, 37 DOVER STREET, LONDON, W.1

# Trasicor<sup>®</sup>

oxprenolol hydrochloride

## The fundamental approach to long-term treatment of angina

Trasicor offers a new approach to the treatment of angina

### Highly effective

— Frequency and severity of anginal attacks dramatically reduced

— Trinitrin requirements reduced or eliminated

### Improved safety

— Cardioselective approach to treatment

— Less likely to increase sinus bradycardia

Trasicor goes further than just relief of pain

— it offers a better quality of life

Before using Trasicor, it is important that you read carefully the detailed literature for full prescribing information.

Tablets 40 mg (for angina) and 20 mg, 100's and 500's.  
Basic NHS price 100 x 40 mg: £2.60  
Ampoules 2 mg.

® denotes registered trademark.

Radiotelemetric studies with Trasicor yield intriguing results



**Trasicor**  
**-one jump ahead in angina**

C I B A

# In angina pectoris

# Eraldin

## the latest in long-term protection

- \* protects the heart specifically
- \* extends clinical usefulness
- \* prevents attacks
- \* improves exercise tolerance
- \* reduces myocardial ischaemia
- \* simplifies treatment

# Eraldin

PRACTOLOL

TRADE MARK

the only beta-receptor antagonist with the  
unique safety factor of cardioselectivity

*Detailed information is available on request*



**THE PATHFINDERS**  
Leaders in  
Cardiovascular Research



THE QUEEN'S  
AWARD  
TO INDUSTRY  
1966 1967 1968  
1969 1970

Imperial Chemical Industries Limited, Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire

North-Holland announces volumes 7-13 of the

# Handbook of Clinical Neurology

edited by

P. J. VINKEN\* and G. W. BRUYN\*\*

\*Executive Chief Editor, *Excerpta Medica Foundation; Consultant Neurosurgeon, University Clinics, Amsterdam*

\*\*Consultant Neurologist, *Netherlands Central Military Hospital, Utrecht*

**Editorial Advisory Board:**

RAYMOND D. ADAMS, *Massachusetts General Hospital* - A. BIEMOND, *University of Amsterdam* -  
MACDONALD CRITCHLEY, *The National Hospital, London* - RUSSELL N. DEJONG, *University of  
Michigan, Ann Arbor* - RAYMOND GARCIN, *Hôpital de la Salpêtrière, Paris* - SHIGEO OKINAKA,  
*Toranomon Hospital, Tokyo* - S. REFSUM, *University of Oslo* - K. J. ZÜLCH, *Max-Planck-Institute, Cologne*

- Vol. 7: Diseases of Nerves, Part I**  
ca. 750 p. *Full price:* Hfl. 230.- (\$64.00;  
£26.17.-)  
*Subscr. price:* Hfl. 195.- (\$54.00; £22.13.-)
- Vol. 8: Diseases of Nerves, Part II**  
566 p. *Full price:* Hfl. 185.- (\$51.50;  
£21.10.-)  
*Subscr. price:* Hfl. 157.- (\$44.00; £18.6.-)
- Vol. 9: Multiple Sclerosis and other Demyelinating  
Diseases**  
ca. 700 p. *Full price:* Hfl. 230.- (\$64.00;  
£26.17.-)  
*Subscr. price:* Hfl. 195.- (\$54.00; £22.13.-)
- Vol. 10: Leucodystrophies and Lipidoses**  
ca. 650 p. *Full price:* Hfl. 200.- (\$55.50;  
£23.6.-)  
*Subscr. price:* Hfl. 170.- (\$47.00; £19.16.-)

- Vol. 11: Vascular Diseases of the Nervous System,  
Part I**  
ca. 850 p. *Full price:* Hfl. 260.- (\$72.00;  
£30.6.-)  
*Subscr. price:* Hfl. 220.- (\$61.00; £25.12.-)
- Vol. 12: Vascular Diseases of the Nervous System,  
Part II**  
ca. 800 p. *Full price:* Hfl. 240.- (\$67.00;  
£28.-.-)  
*Subscr. price:* Hfl. 204.- (\$57.00; £23.16.-)
- Vol. 13: Neuroretinal Degenerations and Phacomatoses**  
ca. 750 p. *Full price:* Hfl. 250.- (\$70.00;  
£29.4.-)  
*Subscr. price:* Hfl. 210.- (\$58.50; £24.10.-)

**ALREADY AVAILABLE:**

- Vol. 1: Disturbances of Nervous Function**  
711 p. *Full price:* Hfl. 240.- (\$67.00; £28.-.-)  
*Subscr. price:* Hfl. 204.- (\$57.00; £23.16.-)
- Vol. 2: Localization in Clinical Neurology**  
814 p. *Full price:* Hfl. 225.- (\$63.00; £26.5.-)  
*Subscr. price:* Hfl. 191.25 (\$53.75; £22.6.-)
- Vol. 3: Disorders of Higher Nervous Activity**  
454 p. *Full price:* Hfl. 126.- (\$35.00; £14.14.-)  
*Subscr. price:* Hfl. 107.10 (\$29.75; £22.10.-)
- Vol. 4: Disorders of Speech, Perception and  
Symbolic Behaviour**  
492 p. *Full price:* Hfl. 156.- (\$44.00; £18.4.-)  
*Subscr. price:* Hfl. 132.60 (\$37.50; £15.9.-)
- Vol. 5: Headaches and Cranial Neuralgias**  
426 p. *Full price:* Hfl. 129.- (\$36.00; £15.1.-)  
*Subscr. price:* Hfl. 109.65 (\$30.50; £12.16.-)
- Vol. 6: Diseases of the Basal Ganglia**  
901 p. *Full price:* Hfl. 227.- (\$77.00; £32.6.-)  
*Subscr. price:* Hfl. 235.45 (\$65.50; £27.10.-)

**Subscription Scheme:**

The entire work will consist of thirty volumes to be published over a period of about 8 years. All volumes can be ordered separately. However, subscribers to the complete set are entitled to a *discount of 15% on the full publication price*. Each volume will be invoiced separately and supplied immediately upon publication. UNESCO-coupons, cheques or postal transfers are equally acceptable. Payment may also be made in monthly instalments with no increase in cost.

*Please request the extensive brochure for the 'Handbook of Clinical Neurology'*

AMSTERDAM P.O. BOX 3489  NORTH HOLLAND PUBLISHING CO. NETHERLANDS

*Sole distributors for the U.S.A. and Canada: American Elsevier Publishing Company, Inc., New York*  
*Sole distributors in Japan: Igaku Shoin Ltd., Tokyo*

*Sole distributor in Australia and New Guinea: Dutch Australian Book Depot, Pty. Ltd., Melbourne*